Background: Multiple myeloma (MM) is a hematological neoplasm of the early precursor of B-cells. The most characteristic symptoms observed during MM include hypocalcemia, anemia, bacterial infections, and renal damage. Nutritional disorders, especially malnutrition, are noted in about 35–71% of MM patients. Interleukin 1 beta (IL-1β) is a proinflammatory cytokine responsible for muscle atrophy and lipolysis during malnutrition and cachexia. This study aimed to evaluate the usefulness of theIL1Bsingle-nucleotide polymorphism (SNP) (rs1143634) and plasma concentration of IL-1β in the assessment of the risk of nutritional disorders and prognosis in patients with MM. Methods: In our study, 93 patients with the de novo MM were enrolled. The real-time PCR with specific TaqMan probes method was used in genotyping. The IL-1β ELISA kit was used to determine IL-1β concentration in plasma samples. Results: Patients with the CC genotype, compared to the carriers of the other variants of theIL1B, demonstrated significantly higher concentrations of IL-1β in plasma (7.56 vs. 4.97 pg/mL), a significantly higher risk of cachexia (OR = 5.11), and a significantly higher risk of death (HR = 2.03). Moreover, high IL-1β plasma level was related to a significantly higher risk of cachexia (OR = 7.76); however, it was not significantly associated with progression-free survival (PFS) or overall survival (OS). Conclusions: Determination of theIL1BSNP (rs1143634) and plasma concentration of IL-1β may be useful in the assessment of the risk of cachexia and prognosis in patients with MM.
背景：多发性骨髓瘤（MM）是一种起源于B细胞早期前体细胞的血液系统恶性肿瘤。该病最典型的临床表现包括低钙血症、贫血、细菌感染及肾功能损害。约35%-71%的MM患者存在营养紊乱，特别是营养不良现象。白细胞介素1β（IL-1β）作为一种促炎细胞因子，在营养不良及恶病质状态下可导致肌肉萎缩和脂肪分解。本研究旨在评估IL1B基因单核苷酸多态性（SNP）（rs1143634）及血浆IL-1β浓度对MM患者营养紊乱风险及预后评估的临床价值。 方法：本研究共纳入93例初诊MM患者。采用特异性TaqMan探针实时荧光定量PCR法进行基因分型，使用IL-1β ELISA试剂盒测定血浆样本中IL-1β浓度。 结果：与携带IL1B其他基因型的患者相比，CC基因型患者表现出显著更高的血浆IL-1β浓度（7.56 vs. 4.97 pg/mL）、显著增加的恶病质风险（OR = 5.11）及显著升高的死亡风险（HR = 2.03）。此外，高血浆IL-1β水平与显著增高的恶病质风险相关（OR = 7.76），但与无进展生存期（PFS）或总生存期（OS）无显著相关性。 结论：检测IL1B基因SNP（rs1143634）及血浆IL-1β浓度可能有助于评估MM患者的恶病质风险及预后判断。
肿瘤(癌症)患者之家